Evidence map›Paper›PMID 29421849›Full record

ArticleRapid communications in mass spectrometry : RCM2018

A validated liquid chromatography/tandem mass spectrometry method for the analysis of efavirenz in 0.2 mg hair samples from human immunodeficiency virus infected patients.

Jenna Johnston, Catherine Orrell, Peter Smith, Anton Joubert, Lubbe Wiesner

Open access · greenAbstract readValidation Study
In one paragraph

Article in Rapid communications in mass spectrometry : RCM, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Jenna JohnstonDivision of Clinical Pharmacology, University of Cape Town, Cape Town, South Africa.ORCID http://orcid.org/0000-0002-7817-1016
Catherine OrrellDesmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine and Department of Medicine, University of Cape Town, Cape Town, South Africa.
Peter SmithDivision of Clinical Pharmacology, University of Cape Town, Cape Town, South Africa.
Anton JoubertDivision of Clinical Pharmacology, University of Cape Town, Cape Town, South Africa.
Lubbe WiesnerDivision of Clinical Pharmacology, University of Cape Town, Cape Town, South Africa.
University of Cape Town · ZADesmond Tutu HIV Foundation · ZA

Funding

Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1M
Use of ARV Drug Levels in DBS to Assess and Manage ART Adherence in South AfricaR01AI122300 · NIAID · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI ORRELL, CATHERINE, REMIEN, ROBERT H · 2016 to 2020
$4.6M
NIAID NIH HHS R01 AI122300NIAID NIH HHS UM1 AI068636
6 · The paper itself

Abstract

rationaleDrug levels in hair provide a longer window of detection, compared to plasma drug levels, and therefore hair analysis has the advantage of assessing adherence over a longer period of time. No methods for the analysis of antiretroviral drugs in hair currently exist in South Africa, and worldwide there is only one validated method for the determination of efavirenz in hair that has been published.

methodsEfavirenz was extracted from 0.2 mg of hair through a simultaneous pulverization and extraction step. Separation was achieved on an Agilent Poroshell C18 column using an isocratic elution with a total run time of 3 min. A triple quadrupole mass spectrometer set to electrospray ionization in positive multiple reaction monitoring mode was used for detection. The method was validated over the concentration range 0.625-40 ng/mg.

resultsUsing ten times less hair than in a previously published method, the lower limit of quantitation was validated at 0.625 ng/mg. The interday and intraday assay precision, expressed as the percentage coefficient of variation (CV), for spiked calibration standards and quality control samples was lower than 7% and accuracy ranged from 97 to 110%. For quality controls prepared from authentic hair the CV was less than 12%. The extraction efficiency for authentic quality control samples was determined to be 83% after repeated extractions of the same samples.

conclusionsThis paper reports the first quantitative method for the determination of efavirenz in hair to be developed in South Africa. The validated method allowed for the successful monitoring of efavirenz in hair collected from HIV-infected patients as part of a clinical study.

Indexed as

AlkynesBenzoxazinesChromatography, LiquidCyclopropanesDrug MonitoringFemaleHairHIVHIV InfectionsHumansLimit of DetectionMaleReverse Transcriptase InhibitorsTandem Mass SpectrometryAlkynesBenzoxazinesCyclopropanesefavirenzReverse Transcriptase Inhibitors

Identifiers

PMID29421849
PMCPMC5882196
OpenAlexW2790169244

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.